Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision OncologyGlobeNewsWire · Oct 16, 2026
Aprea Therapeutics to Present at October ConferencesGlobeNewsWire · Oct 5, 2026
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR SymposiumGlobeNewsWire · Sep 22, 2026
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 10, 2026
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology ProgramsGlobeNewsWire · Aug 28, 2026
Aprea Therapeutics Announces Second Quarter 2026 Financial ResultsGlobeNewsWire · Aug 12, 2026Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.18 | -$0.07 | Beat |
| May 13, 2026 | -$0.23 | -$0.22 | Beat |
| Mar 16, 2026 | -$0.38 | -$0.32 | Beat |
| Nov 12, 2025 | -$0.11 | -$0.47 | Miss |
| Aug 12, 2025 | -$0.77 | -$0.53 | Beat |
| May 14, 2025 | -$0.65 | -$0.66 | Miss |